Holen Sie sich die Stockscreener-App
121.50
0.69%
-0.85
Vorhandelsmarkt:
120.38
-1.12
-0.92%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ILMN?
Forum
Prognose
Aktiensplit
Illumina Inc Aktie (ILMN) Neueste Nachrichten
Illumina partnership aims to speed rare disease diagnosis in Florida - AADC News
Illumina Stock Climbs 44.8% in a Year: What's Driving the Rally? - The Globe and Mail
Bioinformatics Market to Reach US$ 29.1 Billion by 2031 Growing - openPR.com
Capital International Inc. CA Boosts Stake in Illumina - National Today
Capital International Inc. CA Boosts Stock Holdings in Illumina, Inc. $ILMN - MarketBeat
Inceptionr LLC Invests in Illumina, Inc. - National Today
Here’s Why Illumina Stock Could Continue Its 44% Recovery Into 2026 - TIKR.com
Capital World Investors Acquires 3,331,542 Shares of Illumina, Inc. $ILMN - MarketBeat
Capital International Sarl Buys 24,055 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. $ILMN Stock Holdings Increased by Capital International Ltd. CA - MarketBeat
Epigenetics Market to Reach US$ 7.10 Billion by 2033 at 14.8% CAGR - openPR.com
Inceptionr LLC Makes New Investment in Illumina, Inc. $ILMN - MarketBeat
Molecular Diagnostics Market Outlook: Set to Grow at 10%+ CAGR Through 2031 as Precision Medicine and Genetic Testing Advance, Says Mordor Intelligence - GlobeNewswire Inc.
How Singapore is solidifying its role at the forefront of global genomics - Illumina
Here's Why Illumina (ILMN) is a Strong Momentum Stock - Yahoo Finance
Neuberger Berman Group LLC Purchases 8,135 Shares of Illumina, Inc. $ILMN - MarketBeat
Neo Ivy Capital Management Invests $1.83 Million in Illumina, Inc. $ILMN - MarketBeat
Illumina Regeneron Alliance Targets Multiomics And Raises Valuation Questions - Yahoo Finance UK
Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset - marketscreener.com
Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering - Illumina
Illumina (ILMN) Gaining from Stronger Than Expected Results - Insider Monkey
How Illumina Inc. (ILMN) Affects Rotational Strategy Timing - Stock Traders Daily
TEM's Diagnostics Arm Expanding Rapidly: What's Driving the Growth? - TradingView
Integrated Quantitative Investments LLC Acquires New Holdings in Illumina, Inc. $ILMN - MarketBeat
Elo Mutual Pension Insurance Co Makes New Investment in Illumina, Inc. $ILMN - MarketBeat
ARK Investment Management Boosts Stake in Illumina - National Today
ARK Investment Management LLC Has $139.41 Million Position in Illumina, Inc. $ILMN - MarketBeat
Amova Asset Management Americas Inc. Increases Stake in Illumina, Inc. $ILMN - MarketBeat
Why Illumina (ILMN) is a Top Growth Stock for the Long-Term - Nasdaq
DNA Microarray Market is expected to reach US$ 6.12 billion - openPR.com
Illumina Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
ILMN: Sequencing innovation, clinical growth, and end-to-end solutions drive strong outlook - TradingView
PacBio and DNAstack Collaborate on Global HiFi Genome Network Hub - TradingView
10,000 Shares in Illumina, Inc. $ILMN Bought by Strive Asset Management LLC - MarketBeat
ILMN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Handelsbanken Fonder AB Boosts Stake in Illumina, Inc. $ILMN - MarketBeat
Is Illumina’s (ILMN) TruPath Rare Disease Push Reframing Its Clinical Sequencing Investment Narrative? - simplywall.st
Illumina Inc. stock underperforms Monday when compared to competitors - MarketWatch
Illumina Inc (ILMN) Trading Down 2.84% on Mar 2 - GuruFocus
Illumina, Inc. (ILMN) Stock Analysis: Exploring The Upside With A 33% Return On Equity - DirectorsTalk Interviews
Why Illumina (ILMN) Is Up 14.3% After Launching TruPath Genome And Expanding Rare-Disease Sequencing - Yahoo Finance
Illumina: Competitive Pressures Mounting but 2026 Revenue Targets Still Intact, Justifying a Hold Rating - TipRanks
Andra AP fonden Buys 58,209 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. $ILMN Position Boosted by Citigroup Inc. - MarketBeat
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected MultiomicsPR Newswire APAC - PR Newswire Asia
Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida - Illumina
Primecap Management Co. CA Sells 73,220 Shares of Illumina, Inc. $ILMN - MarketBeat
Evercore ISI reiterates Illumina stock rating on competitive positioning By Investing.com - Investing.com Australia
Illumina Launches TruPath Genome Unveils NovaSeq X Roadmap and Drives Cancer Breakthroughs with Connected Multiomics - theweek.in
Illumina Inc. Unveils Revolutionary Genomic Advancements - Devdiscourse
[PRNewswire] Illumina Launches TruPath Genome - Yonhap News Agency
The next generation is shaping the future of rare diseases - Illumina
Evercore ISI reiterates Illumina stock rating on competitive positioning - Investing.com
Canaccord reiterates Illumina stock Hold rating after Roche pricing By Investing.com - Investing.com South Africa
Canaccord reiterates Illumina stock Hold rating after Roche pricing - Investing.com Nigeria
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Present - PharmiWeb.com
0.17%
0.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):